123TiP - Study 20070782: randomized phase 3 trial of the long-term safety of darbepoetin alfa in patients with non-small cell lung cancer (NSCLC) with chemot...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Complications of Treatment
Supportive Care
Non-Small-Cell Lung Cancer, Metastatic
Presenter Pere Gascon
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors P. Gascon1, C.H. Barrios2, D. Gordon3, V. Hirsh4, S. Orlov5, K. Syrigos6, C. Volovat7, L. Zhang8, C. Bohac9
  • 1Division Of Medical Oncology, Hematology-oncology Department, Hospital Clinic, Barcelona University, 08036 - Barcelona/ES
  • 2Department Of Medicine, PUCRS School of Medicine, Porto Alegre RS/BR
  • 3Oncology, Cancer Care Centers of South Texas, San Antonio/US
  • 4Oncology, McGill University, Quebec/CA
  • 5University N.a.academic I.p.pavlov Of Moh And Sd Of Rf, SBEI of HPE Saint Petersburg State Medical, St Petersburg/RU
  • 6Sotiria General Hospital, Athens School of Medicine, Athens/GR
  • 7Oncology, Center of Medical Oncology, IASI/RO
  • 8Medical Oncology, Sun Yat-Sun University Cancer Center, Guangzhou/CN
  • 9Clinical Development, Amgen Inc., Thousand Oaks/US


Controlled trials have shown erythropoiesis-stimulating agents (ESAs) raise hemoglobin (Hb) and reduce transfusions in patients with CIA. While some suggestions of increased mortality and/or tumor progression have been raised in a few trials, most studies to date have not associated the use of ESAs with worse outcomes. As CIA often develops in lung cancer, studying ESA safety in NSCLC is warranted.